Myeloproliferative Disease (MPD) Program

Myeloproliferative disorders (MPD) are a group of slow-growing blood cancers in which large quantities of abnormal red blood cells, white blood cells, or platelets grow and spread in the bone marrow. The MPD Program at The Tisch Cancer Institute at Mount Sinai is one of few comprehensive, multidisciplinary programs in the Northeast offering extraordinary expertise and personalized treatments, backed by extensive research and clinical trials.
Our physicians at Mount Sinai treat all types of MPD diseases, including:

  • Polycythemia Vera Essential
  • Thrombocythemia
  • Chronic Myeloid Leukemia Primary
  • Myelofibrosis Polycythemia Vera
  • Essential Thrombocythemia Chronic
  • Myeloid leukemia Primary Myelofibrosis
  • Polycythemia Vera Essential
  • Thrombocythemia Chronic Myeloid
  • Leukemia Primary Myelofibrosis
  • Polycythemia Vera Essential
  • Thrombocythemia Chronic Myeloid
  • Leukemia Primary Myelofibrosis

Our Multidisciplinary MPD Program Team

Treatment for myeloproliferative diseases involves a team approach that brings together specialists with expertise in various disciplines in order to provide comprehensive, personalized care, as well as comfort to patients and their caregivers. At Mount Sinai, our team includes transplant physicians, infectious disease doctors, nutritional support, surgeons, cardiologists, pathologists, compassionate nurses, counseling services, and other supportive staff.

MPD Disease Treatment

While MPD can be challenging to treat, our physicians and researchers are at the forefront of developing and utilizing the latest therapies to treat and control symptoms of it. These treatments and therapies include:

  • Medications
  • Blood or platelet transfusion
  • Radiation therapy
  • Bone marrow growth factors
  • Bone marrow transplant
  • Phelebotomy

Innovative MPD Program Research at Mount Sinai  

Under the leadership of Ronald Hoffman, MD, the MPD Program combines clinical care with clinical trial offerings and a dedicated laboratory at the Icahn School of Medicine at Mount Sinai. Patients have access to a number of phase I/II trials for those with Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia. Research activities at our lab are focused on defining the molecular underpinnings of these neoplasms, and identifying and testing novel agents in preclinical studies that will one day be used in early phase clinical trials.

Dr. Hoffman is also the principal investigator of the MPD Consortium, a NCI-sponsored program of 35 institutions in the United States and Europe, of which Mount Sinai is the lead site. The consortium focuses on understanding the biological foundations of the myeloproliferative neoplasms and using that understanding to develop hypothesis-generated therapeutic trials to improve the therapy of patients.

Contact Us

To make an appointment:
212-241-6021